Core Viewpoint - The company has no products for treating Chikungunya virus but is conducting antiviral activity tests with existing and in-development drugs [1] Group 1 - The company stated on an interactive platform that it currently has no products for treating Chikungunya virus [1] - The company's subsidiary, Zhongsheng Ruichuang, is conducting in vitro antiviral activity tests using the already marketed innovative drug, Anladiwei, and an in-development drug against the Chikungunya virus [1] - Preliminary results indicate that both Anladiwei and the in-development drug show strong inhibitory activity against the Chikungunya virus [1] Group 2 - The company plans to continue gathering more experimental data and will monitor the virus's epidemic situation to assist in disease prevention and control efforts [1]